Last reviewed · How we verify
Ofatunumab
At a glance
| Generic name | Ofatunumab |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (PHASE4)
- Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ofatunumab CI brief — competitive landscape report
- Ofatunumab updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI